Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Atrium Therapeutics Shares Rise 5% in 1 Day Since ATR 1072 Reverses Cardiac Glycogen

Atrium Therapeutics Reports ATR 1072 Reverses Cardiac Glycogen in PRKAG2 Syndrome Models

+5.68% in 1 day $8.27 when we broke this story → $8.74 at 11:07 AM ET, 3 Nov 2026

Atrium Therapeutics announced nonclinical data for its lead RNA therapy, ATR 1072, showing the reversal of cardiac glycogen accumulation in models of PRKAG2 syndrome. The findings support the ongoing Corventis Phase 1/2 clinical trial, with initial proof-of-concept data anticipated in the second half of 2027.

Medications, tablets, medicine, cure. Stock photo illustrating Atrium Therapeutics' other story.
Atrium Therapeutics, Inc. · Healthcare · Photo: Pexels / Pixabay

Key highlights

  • Nonclinical results showed reversal of cardiac glycogen accumulation and improvement in hypertrophy
  • Company developed a new mouse model reproducing key PRKAG2 syndrome features including ECG abnormalities
  • Data scheduled for presentation at the American Heart Association Scientific Sessions 2026 on November 6
  • Corventis Phase 1/2 trial aims to enroll approximately 37 participants to evaluate safety and efficacy
  • Cash runway expected to fund operations through 2028 following recent $50 million private placement

Nonclinical Findings and Presentation

Atrium Therapeutics disclosed new nonclinical data for ATR 1072, an investigational RNA therapy targeting the underlying genetic driver of PRKAG2 syndrome. In a company-developed mouse model, a single dose of a mouse-surrogate version of ATR 1072 led to the reversal of established cardiac glycogen accumulation and improvements in hypertrophy and electrocardiogram parameters. These results will be presented at the Hypertrophic Cardiomyopathy Medical Society during the American Heart Association Scientific Sessions 2026 in Chicago. The data reinforce the scientific rationale for targeting PRKAG2 mRNA to address the symptoms of this rare, early-onset cardiomyopathy.

Clinical and Operational Milestones

  • Initial proof-of-concept data from the Corventis Phase 1/2 clinical trial is expected in the second half of 2027
  • The Corventis trial is an open-label study evaluating safety, pharmacokinetics, and efficacy in 37 participants
  • PRKAG2 syndrome currently has no approved therapies to address the genetic cause of the disease
  • Atrium was established as an independent entity in February 2026 following a spin-off from Avidity Biosciences
  • The company holds a cardiovascular collaboration with Bristol Myers Squibb, having earned $30 million in milestones this year

Chief Scientific Officer Perspective

“We are encouraged to see that a mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and improved other key features of the disease. These findings continue to strengthen the scientific rationale for ATR 1072.”

Husam Younis, Chief Scientific Officer, Atrium Therapeutics

Financial Position and Market Context

Atrium Therapeutics maintains a market capitalization of approximately $141.5 million with a current share price of $8.27. In October 2026, the company secured a $50 million private placement of common stock and pre-funded warrants, which is expected to provide sufficient liquidity for operations through 2028. This financial stability supports the continued advancement of the Corventis trial and the broader targeted RNA delivery platform. The company reported annual revenue of $18.6 million for the prior period, largely driven by strategic partnership milestones, while continuing its focus on the precision cardiology sector.

Atrium Therapeutics, Inc. share price · last month
Line chart of Atrium Therapeutics, Inc.'s share price over the last month, from $7.61 on 19 Oct → $6.43 on 16 Nov; our story on 2 Nov at $8.27.

Down 22.2% since our story on 2 Nov: $8.27 when we broke it → $6.43 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$7.61
20 Oct$7.98
21 Oct$8.00
22 Oct$8.16
23 Oct$8.20
26 Oct$8.05
27 Oct$8.32
28 Oct$8.40
29 Oct$8.26
30 Oct$8.27
2 Nov$8.55
3 Nov$8.72
4 Nov$8.68
5 Nov$8.32
6 Nov$8.34
9 Nov$8.38
10 Nov$8.23
11 Nov$7.96
12 Nov$7.50
13 Nov$7.51
16 Nov$6.43
Earlier announcements by Atrium Therapeutics, Inc.
DateAnnouncementAmount
27 Oct 2026Dosed first patient in the Phase 1/2 Corventis clinical trial of lead candidate ATR 1072 for PRKAG2 syndromeSource: investors.atriumtherapeutics.com–
08 Oct 2026Entered into a securities purchase agreement for a private placement of common stock and pre-funded warrantsSource: streetinsider.com$50.0 Million
13 Aug 2026Reported second quarter 2026 financial results and earned a second milestone payment from Bristol Myers SquibbSource: SEC filing$15.0 Million
14 Jul 2026Received U.S. FDA clearance of Investigational New Drug application for ATR 1072 to treat PRKAG2 syndromeSource: investors.atriumtherapeutics.com–
23 Apr 2026Earned first development milestone payment under cardiovascular collaboration with Bristol Myers SquibbSource: investors.atriumtherapeutics.com$15.0 Million
27 Feb 2026Launched as an independent publicly traded company following spin-off from Avidity BiosciencesSource: investors.atriumtherapeutics.com$270.0 Million

Management commentary

“Our new nonclinical model reproduced many features of PRKAG2 syndrome, including cardiac glycogen accumulation in the heart. We are encouraged to see that a mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and improved other key features of the disease.”

Husam Younis, Chief Scientific Officer
Atrium Therapeutics, Inc. · financial snapshot
Share price$8.27
Market cap$141M
Revenue (annual)$19M
1-month price change-0.12%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Atrium Therapeutics, Inc. announcing nonclinical data for ATR 1072 for the treatment of PRKAG2 syndrome.

Read the filing ↗
All Atrium Therapeutics, Inc. filings and newsView all →

Track Atrium Therapeutics, Inc. live

Get the next Atrium Therapeutics, Inc. SEC filing seconds after it lands.

More from Atrium Therapeutics, Inc.

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.